Before GMP: Six manufacturing considerations gene therapy sponsors should address earlier
SK pharmteco’s Tatiana Nanda, chief technical officer of SK pharmteco Viral Vector North America discusses what gene therapy sponsors must account for sooner rather than later when preparing for GMP manufacturing.
comments(0)
5-min edit window · permanent after that